TCBIO Texas Capital Bancshares Forecast, Technical & Fundamental Analysis

TCBIO in downward trend: price dove below 50-day moving average on September 01, 2026

TCBIO moved below its 50-day moving average on September 01, 2026 date and that indicates a change from an upward trend to a downward trend. In 30 of 54 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 56%.

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TCBIO as a result. In 43 of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 51%.

The Moving Average Convergence Divergence Histogram (MACD) for TCBIO turned negative on September 01, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 46 similar instances when the indicator turned negative. In 22 of the 46 cases the stock turned lower in the days that followed. This puts the odds of success at 48%.

The 10-day moving average for TCBIO crossed bearishly below the 50-day moving average on September 08, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 8 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 42%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 45%.

The Aroon Indicator for TCBIO entered a downward trend on October 01, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where TCBIO's RSI Indicator exited the oversold zone, 18 of 29 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 62%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 22 of 51 cases where TCBIO's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 43%.

TCBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TCBIO's P/B Ratio (0.000) is very low in comparison to the industry average of (1.321). P/E Ratio (0.000) is within average values for comparable stocks, (24.015). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.186). TCBIO's Dividend Yield (0.078) is considerably higher than the industry average of (0.030). TCBIO's P/S Ratio (0.000) is very low in comparison to the industry average of (3.747).

The Tickeron Price Growth Rating for this company is 71 (best 1 - 100 worst), indicating slightly worse than average price growth. TCBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 57, placing this stock worse than average.